As a mechanism by which CHRNB2 inhibits the metastasis of CRC, CHRNB2 has been reported to mediate cell survival, resistance to anticancer drugs, and stemness of cancer cells by inhibiting the activity of components of the PI3K–AKT and JAK–STAT signaling pathways [15]. Here, AKT1 is linked to colorectal carcinoma.